Preview

Case Analysis Pepcid Ac Racing to the Otc Market

Better Essays
Open Document
Open Document
1255 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Case Analysis Pepcid Ac Racing to the Otc Market
MBA 560 – Marketing Principles

Case Analysis
Pepcid AC Racing to the OTC Market

The managers at Johnson & Johnson/Merck Consumer Pharmaceuticals Co. (JJM) have two options regarding their newest over-the-counter (OTC) drug Pepcid AC. The first option would be to pursue both claims of treatment and prevention, which would help differentiate their drug from other competitors OTC drugs that are also pending FDA approval. The first option could require up to 9 months of additional studies and investments to provide further evidence to the advisory committee and FDA. Conversely, they could choose the second option, to bypass the recommendations of the advisory committee and take their case directly to the FDA with the goal of being the first to enter the market. If they choose the second option, they would also need to decide whether to request approval for both claims or just the treatment claim. Option two is the best course of action based on the evidence and data presented in the case. They should only seek approval of the treatment claim and work to get the required additional evidence for the prevention claim approval in the near future to differentiate as more drugs enter the OTC market.
All marketing claims regarding “the uses, benefit, or efficacy of any drug” (King, et al. 2003) require approval by the FDA. JJM progress toward approval for Pepcid AC as an OTC heartburn remedy was stalled in late July of 1994. The advisory committees requested additional evidence to support JJM’s claims that Pepcid AC prevented and/or provided relief from heartburn. JJM’s largest competition for first-to-market was SmithKline Beecham’s drug Tagamet, which had also been stalled by the advisory committee for the FDA. At one time JJM had conceded the first-to-market slot SmithKline Beecham due to the recent decisions of the advisory board they had an opportunity to be first-to-market. This is the optimal time for JJM to enter the highly competitive



Bibliography: Kim, W. Chan, and Renee Mauborgne. "Blue Ocean Strategy." Harvard Business Review, 2004: 10. King, Charles III, Alvin J. Silk, Lisa R. Klein, and Ernst R. Berndt. "Pepcid AC: Racing to the OTC Market." Harvard Business School, June 2003: 15.

You May Also Find These Documents Helpful

  • Good Essays

    Over-the-counter market growth is attractive to pharmaceutical companies like P&G who successfully changed Aleve from prescription strength to OTC. Once the patent for Pepcid expires in six years there will inevitably be fierce competition. Since the FDA usually takes so long to process an approval for a prescription-to-OTC switch, JJM can go through the process while they still have patent protection for Pepcid and get a stronghold on the market. Also, Pepcid is a treatment for a common chronic problem that is relatively easy to self-diagnose and treat. An OTC Pepcid would…

    • 619 Words
    • 3 Pages
    Good Essays
  • Good Essays

    References: Kim, W. C., & Mauborgne, R. (2004). BLUE OCEAN STRATEGY. Harvard Business Review, 82(10), 76-84.…

    • 777 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Bios275 - Week1

    • 522 Words
    • 3 Pages

    Phase III – Performance of drug administered as intended once on market. Compared with other drugs currently on market for same illnesses.…

    • 522 Words
    • 3 Pages
    Good Essays
  • Powerful Essays

    The Medicines Company

    • 868 Words
    • 5 Pages

    The Medicines Company Case Write-Up: Terence Cho, Felipe Duarte, Aleks Loiko, Robert Shaw, and James Wang…

    • 868 Words
    • 5 Pages
    Powerful Essays
  • Good Essays

    References: Kim, W. & Mauborgne, R. (2004). Blue Ocean Strategy. Harvard Business Review, 82(10), 76–…

    • 957 Words
    • 3 Pages
    Good Essays
  • Good Essays

    PROCEDURAL HISTORY: Section 503A of the Food, Drug and Cosmetic Act, 21 U.S.C. § 353a exempts compounded drugs from certain provisions of the Food and Drug Administration’s standard approval requirements; provided that the distributors abide by certain restrictions, including advertising and promoting selected compounded drugs. The Act, however, did not prohibit the advertising of its effectiveness. The Central Hudson Gas et. Elec. Corp v. Public Serv. Comm’n of NY, 447 U.S. 557, 566 held that the restrictions directly advance its interests, or that less restrictive alternatives were unavailable.…

    • 421 Words
    • 2 Pages
    Good Essays
  • Good Essays

    Blue Ocean Strategy

    • 749 Words
    • 3 Pages

    Kim, W.C. & Mauborgne, R. (2004). Blue ocean strategy. Harvard Business Review. Retrieved from http://hbr.org/2004/10/blue-ocean-strategy/ar/1…

    • 749 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Prescription drug companies can have their drugs reach the market much faster than in the past. Approval time from the FDA went from 27 months in 1993 to 14 months in 2001, saving a company an estimated $41.7 million in lost revenue a month. This would benefit internal as well as external stakeholders. In 1997 the FDA allowed drug companies to advertise directly-to-consumers (DTC), which proved to be very beneficial…

    • 553 Words
    • 3 Pages
    Good Essays
  • Satisfactory Essays

    Pepcid Ac

    • 966 Words
    • 4 Pages

    The major hurdle in launching Pepcid AC as an OTC drug was getting it approved by FDA. JJM pursued. Tagamet had an early lead in the FDA approval process. JJM was pursuing a strategy comprising of both a treatment and a prevention claim to launch Pepcid AC in the OTC market. However, FDA advisory committee rejected SmithKline Beecham 's proposal for Tagamet in 1993 and in the following year also rejected JJM 's proposal for Pepcid AC. FDA approval process for an OTC medication requires demonstrating the efficacy of the low dosage drug,…

    • 966 Words
    • 4 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Questions 6

    • 535 Words
    • 2 Pages

    Underutilization of new effective drugs is a serious concern for pharmaceutical companies. There are many restrictions on pharmaceuticals companies to make their drug available for everyone. Certain restrictions like Medicaid will only allow specific medicine to be reimbursable. If a…

    • 535 Words
    • 2 Pages
    Satisfactory Essays
  • Powerful Essays

    This has led to the convention of the NSURE (Nonprescription Safe Use Regulatory Expansion) initiative, which aims to expand the regulatory constraints associated with the non-prescription drug category, in hopes of providing increased access to adequate medical care for the public. The NSURE initiative was conceptualized to aid the process of Rx-to-OTC switches by expanding the ‘Conditions of Safe Use’. According to the presentation of Theresa M. Michele, MD, Director, Division of Nonprescription Clinical Evaluation of the FDA, at a conference on OTC drugs held in October 2014, the existing switch process has a few limitations, mentioned below. • The purchase decision for the OTC drugs is based only on the information conveyed through the Drug Facts label and the principal display panel • The switch process is restricted in its communication with the consumer and doesn’t take…

    • 1315 Words
    • 6 Pages
    Powerful Essays
  • Powerful Essays

    As Joseph Crowley once said, “Some of the FDA's own scientists have charged that politics, not science, is behind the FDA's actions”. Such thoughts contribute to the notion of how the Food and Drug Administration (FDA) is in need of reform. When Americans go to the pharmacy, drug store, or any other place in order to purchase medications, they expect to receive quality products. The organization known as the FDA has been put in charge of keeping the public healthy, yet evidence from the past shows this is not the case. With repeated drug recalls, the FDA has lost almost all of its credibility and dependability, and it must be reformed through the introduction of a new administration to work alongside the FDA in order to stop some mistakes from reoccurring. With such a solution, the FDA can become what it was initially intended to be.…

    • 1475 Words
    • 6 Pages
    Powerful Essays
  • Good Essays

    What Is Biased Research

    • 615 Words
    • 3 Pages

    Consequently, happened that Avandia drug had influenced documentation on the dangerous side effects that remained unknown. One assumption is an individual taking the drug that the research had gone through a rigorous test. The FDA learned about the dangerous side effects that caused heart attacks and required that the GlaxoSmithKline drug maker of Avandia drug to perform a study to determine the possible dangers. Although, GlaxoSmithKline drug research denied information from the FDA. The FDA started bias restriction research that drug manufacturers would have to release publications of data showing medication side effects. Therefore, as a consumer, it's hard to trust the result of the pharmaceutical making companies, research that is bias instead of truth and This doesn’t happen because it is challenging for the consumer to believe them. However, GlaxoSmithKline continues to hide data and remains biased over incomplete information that sanctions profit without concern for the medical health of individuals. Therefore, the pharmaceutical researchers remain biased because they just did not conduct scientific analyzing of rigorous testing and publishing the full…

    • 615 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Blue Ocean Strategy

    • 814 Words
    • 3 Pages

    The Blue Ocean Strategy is like a unique business, a blue fish, in the picture below, offering a product or service that has particular characteristics different from all the rest of the…

    • 814 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Biomax Case Summary

    • 1049 Words
    • 5 Pages

    The Company's primary strategy is to get those prescriptions surrendered by other pharmaceutical organizations. Despite the fact that the Company has received 4 standards to screen among the competitors, in any case it confronts the potential danger of disappointment. Drug organizations relinquished these items for a mixture of great reason including security, viability and benefit potential. Why does the Medicines Company have the Golden Finger? There is no such ensure that items which consent to the 4 criteria will end up being a blockbuster product. The Company seems to fail to offer an agreeable advertising arrangement for Angiomax and other future medications that are coming to company regarding to FDA. So we should stay sensible about…

    • 1049 Words
    • 5 Pages
    Good Essays